The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

This is a 24-week, single-center, randomized, open-label trial conducted by Peking Union Medical College Hospital. The aim of this study is to assess the efficacy and safety of deucravacitinib in adult patients with relapsing TAK in comparison to patients treated with TNF inhibitor (TNFi), the most well-recognized therapeutic choice of non-glucocorticoid immunosuppressive for patients with relapsed or refractory TAK.

NCT Number	NCT07013838
Lead Sponsor	Chinese SLE Treatment And Research Group
Conditions	Takayasu Arteritis (TAK)
Enrollment	50 participants
Start Date	2025-06-15
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-06-10